Abstract: Immature cells of the mononuclear phagocyte series differentiate in response to calcitriol. This is accompanied by increased expression of both CD11b and CD14 and has been shown to be phosphatidylinositol 3-kinase (PI3K) dependent. The events downstream of PI3K that regulate mononuclear phagocyte gene expression, however, remain to be fully understood. In the present study, we show that incubation of THP-1 cells with calcitriol brings about activation of the myeloid zinc finger-1 (MZF-1) transcription factor dependent upon PI3K. In addition, we show that the proximal promoter regions of both CD11b and CD14 contain functional MZF-1 binding sites that are calcitriol responsive. Site-directed mutagenesis of the putative MZF-1 elements abolished MZF-1 binding to the promoters of both CD11b and CD14. Not only did calcitriol treatment increase MZF-1 DNA binding activity to these sites, but it also up-regulated cellular levels of MZF-1. Silencing of MZF-1 resulted in a markedly blunted response to calcitriol for induction of both CD11b and CD14 mRNA transcript levels. Cell surface expression of CD11b and CD14 was also reduced, but to a lesser extent. Taken together, these results show that MZF-1 is involved downstream of PI3K in a calcitriol-induced signaling pathway leading to myeloid cell differentiation and activation of CD11b and CD14. J. Leukoc. Biol. 84: 000 -000; 2008.
INTRODUCTION
Both the innate and acquired immune systems rely heavily upon the effector and regulatory activities of monocytes and macrophages [1] , and recent research has highlighted the important role of phosphoinositides in mononuclear phagocyte cell regulation. Phosphatidylinositide 3-kinase (PI3K) through the production of 3Ј-phosphoinositides has been shown to regulate numerous monocyte/macrophage activities, including cytokine production downstream of Toll-like receptors (TLRs) [2] [3] [4] , phagocytosis [5] , and activation of the phagocyte oxidase [6] , among other properties. These lipid kinases act as crucial signal transducing elements that regulate communication across the plasma membrane. The products of PI3K activity act as lipid secondary messengers that serve to regulate many intracellular responses [7] . Developing a more complete understanding of the agonists that activate monocytes and macrophages through PI3K is important toward understanding the mechanisms of mammalian homeostasis.
One well-studied hormone that has been linked to P13K is 1␣,25-dihydroxyvitamin D 3 , also known as 1,25-dihydroxycholecalciferol or calcitriol. While calcitriol is known best for its role in regulating plasma calcium homeostasis [8 -10] and bone remodeling [11, 12] , it has also been shown to regulate the activities of myeloid cells and to promote host resistance to infection [13] [14] [15] [16] . The latter appears to involve activation of innate immunity through effects on mononuclear phagocytes [17, 18] . Thus, calcitriol promotes phagosome maturation [19] and has been shown to enhance macrophage microbicidal activity toward both Mycobacterium tuberculosis and Salmonella typhimurium [13-15, 20, 21] . Notably, these properties of calcitriol were shown to be PI3K dependent.
Calcitriol induces the differentiation of immature myeloid cells, such as the promonocytic cell line THP-1 along the monocyte/macrophage lineage leading to enhanced expression of the monocyte differentiation markers CD11b and CD14 [10, 22] . CD11b is the ␣ subunit of the integrin cell surface receptor complement receptor 3 and functions in a heterodimer with CD18 to allow recognition and phagocytosis of iC3b opsonized particles. CD11b is exclusively expressed on the surface of mature monocytes, macrophages, neutrophils, and natural killer cells [23] . Consequently, it is a widely used marker for monocyte/macrophage differentiation. CD14, on the other hand, functions in concert with LPS binding protein and TLR-4 in the detection and binding of lipopolysaccharide [24] . Previous studies have shown that CD14 surface expression is increased upon the differentiation of THP-1 cells treated with calcitriol [25] .
The mechanisms by which calcitriol promotes the differentiation of mononuclear phagocytes are not fully understood. Classically, calcitriol regulates gene expression through the vitamin D receptor (VDR). Heterodimerization of VDR with the retinoid X receptor (RXR) and the subsequent translocation of this complex into the nucleus allows targeting of the vitamin D response element (VDRE) in the promoters in a large group of calcitriol-responsive genes [26] . Paradoxically, the CD14 and CD11b promoters do not contain a VDRE [27] , though evidence has been presented to show that calcitriol regulates CD11b and CD14 expression via a phosphatidylinositol 3-kinase (PI3K)-dependent pathway [22] . Many other calcitriolregulated genes that are involved in differentiation also do not contain a VDRE in their promoters, implying that calcitriol regulates these genes via a distinct signaling pathway [10, 22] . Previous studies identified several transcription factors that appear to be involved in regulating expression of CD11b. Sp1 and PU.1 are known to activate the expression of CD11b, while ZBP89 inhibits CD11b expression during myeloid differentiation [28, 29] . It has also been shown recently that CREB functions to promote calcitriol-induced CD14 promoter activity in a PI3K-dependent manner [30] .
The aim of the present study was to examine further the regulation of gene expression in myeloid cells in response to calcitriol. Analysis of the proximal promoters of both CD11b and CD14 identified several candidate binding sites for the transcription factor myeloid zinc finger -1 (MZF-1). These findings, together with its preferential expression in myeloid cells and its role in regulating differentiation suggested that MZF-1 might be calcitriol responsive. In this report, we have shown that MZF-1 is activated by calcitriol and involved in regulating the promoter activities of both CD11b and CD14 downstream of PI3K.
MATERIALS AND METHODS

Reagents and chemicals
Calcitriol (1␣-25 dihydroxyvitamin D 3 ), LY294002, and wortmannin were from Calbiochem (San Diego, CA, USA). RPMI 1640, DMEM, HBSS, penicillin/ streptomycin, PMSF, aprotinin, leupeptin, pepstatin A, and polyisonic:polycytidylic [poly(dI-dC)] were purchased from Sigma Chemical (St. Louis, MO, USA). Restriction enzymes, Taq DNA polymerase, buffers, deoxy-NTPs, T4 DNA ligase, eukaryotic genome extraction kits, and DNA ladder were purchased from Fermentas (Burlington, Ontario, Canada). All custom-synthesized primers, oligos, and FCS were from Invitrogen (Carlsbad, CA, USA). Gel extraction, oligo purification kits, and plasmid isolation kits were purchased from Qiagen (Mississauga, Ontario, Canada). pRL-TK-Renilla reniformis luciferase (Rr-luc), pGL3-Basic, and luciferase detection kits were purchased from Promega (Madison, WI, USA). Transfection reagents were purchased from Invitrogen and Dharmacon RNA Technologies (Lafayette, CO, USA). Anti-MZF-1 antibody was a kind gift from Dorothy Tuan (Medical College of Georgia, Augusta, GA, USA), and anti-actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell lines and cell culture
The human promonocytic cell line THP-1 and the human epithelial carcinoma cell line HeLa were from the American Type Culture Collection (Manassas, VA, USA). THP-1 cells were grown in RPMI 1640 supplemented with 10% FCS, L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 g/ml). Prior to use in most experiments, cells were grown overnight in fresh RPMI/10% FCS from a concentration of ϳ3 ϫ 10 5 cells/ml, then washed with HBSS, and incubated for 5 h in RPMI/0.5% FCS for serum starvation. HeLa cells were cultured in DMEM with nonessential amino acids and 10% FCS, penicillin (100 U/ml), and streptomycin (100 g/ml). Cells were washed in HBSS and incubated in DMEM/0.5% FCS for 5 h for serum starvation.
Nuclear and cytoplasmic protein extraction THP-1 cells were serum starved as previously mentioned. Samples of ϳ2 ϫ 10 7 cells were treated or not treated with PI3K inhibitors LY294002 (10 M) or wortmannin (50 nM) for 45 min, then treated or not treated with calcitriol (100 nM) for 30 min. After washing with HBSS twice, nuclear and cytoplasmic fractions were prepared based on a protocol from the Skirbal Institute of Biomolecular Medicine, New York University Medical Centre (New York, NY, USA) [31] . Cell pellets were then resuspended in 500 l of harvest buffer (10 mM HEPES pH 7.9, 50 mM NaCl, 0.5 M sucrose, 0.1 mM EDTA, 0.5% Triton-X 100, 1 mM DTT, 100 mM NaF, 17.5 mM ␤-glycerophosphate, 1 mM PMSF, and protease inhibitor cocktail (Sigma St. Louis, MO, USA) and incubated on ice for 5 min. Nuclei were pelleted at 7,000 rpm for 6 min at 4°C. The supernatant representing the cytoplasmic fraction was transferred into a new tube, adjusted to 10% glycerol, and stored at -70°C. The nuclei were washed and resuspended in 500 l buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM PMSF, and protease inhibitor cocktail) then centrifuged at 7,000 rpm for 6 min at 4°C. Supernatant was discarded and 40 l of buffer C (10 mM HEPES pH 7.9, 500 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% IGEPAL, 1 mM DTT, 1 mM PMSF, and protease inhibitor cocktail) was added to the pellet. Samples were vortexed for 15 min and kept cool by placing samples on ice intermittently. They were then centrifuged at 11,000 rpm for 20 min at 4°C. This supernatant, representing the nuclear fraction, was transferred to a new tube and adjusted to 10% glycerol. Samples were aliquotted and stored at -70°C. Protein concentrations were measured using the Bio-Rad protein assay kit.
Electrophoretic mobility shift assay
Two to five micrograms of nuclear extract per reaction and 10 ng/l of biotinylated oligonucleotides encoding candidate MZF-1-binding motifs were used. The following custom-synthesized oligonucleotides were used based upon the following sequences in the promoter of CD11b: MZF-1a 5Ј-AGCT-GGGGAG-3Ј at -132 to -122 bp, MZF-1b 5Ј-GGGTGGGCAG-3Ј at -119 to -109 bp and MZF-1c 5Ј-CTCCGCCCTC-3Ј at -57 to -47 bp. The sequence 5Ј-AGGTGGGGAG-3Ј at -89 to -79 bp of the CD14 promoter was also used for synthesis of a fourth biotinylated oligo. Nuclear extract was mixed with binding buffer (20 mM HEPES pH 7.9, 50 mM KCl, 0.1 mM EDTA, 1 mM DTT, 5% glycerol, and 200 g/ml BSA) and 10 g/l of poly (dI-dC). Samples were incubated at room temperature for 5 min then mixed with biotin-labeled oligonucleotides. To control for nonspecific binding, unlabeled oligonucleotide was added in 10-fold excess or a biotin-labeled oligonucleotide containing the mutated sequence of 5Ј-AGCTGAAGAG-3Ј was added prior to the addition of the biotin-labeled oligonucleotide probe. To confirm the identity of the binding protein, a supershift assay was done by the addition of anti-MZF-1 antibody to the samples either prior to or immediately after addition of labeled oligonucleotides. The samples were incubated at room temperature for 30 min, then at 4°C for 30 min. Samples were run on a 6% nondenaturing polyacrylamide gel at 4°C in 0.5ϫ chilled TBE buffer (0.1 M Tris, 0.09 M boric acid and 1 mM EDTA). After electrophoresis, oligonucleotides were transferred to nylon membranes by electrophoresis and UV cross-linked for 3 min. Membranes were then blocked in blocking buffer for 1 h prior to the addition of streptavidin-HRP. After 30 min of incubation, the membranes were washed and developed with ECL solution.
Plasmid construction and site-directed mutagenesis
Genomic DNA was isolated from THP-1 cells using a kit from Fermentas Life Sciences, (#K0512), and the sequence -150 to -20, relative to the transcrip-tion start site from the CD11b promoter, was amplified by PCR using a forward primer with an XhoI site, 5ЈGGCTCGAGGGTATTGACTTTGAAAGTTT-GGGTC-3Ј and a reverse primer with a HindIII site, 5ЈCAGAAGCTTCA-GAAAAGGAGAAGTAGGAGG3Ј. The amplified DNA was extracted from a 1.5% agarose gel using a QIAquick gel extraction kit (Qiagen), digested with XhoI and HindIII, cleaned using QIAquick nucleotide removal kit (Qiagen), and ligated into pGL3-basic (Promega). Plasmids were transformed into TOP10F' competent Escherichia coli, then isolated with a endotoxin free Maxi Prep Kit (Qiagen). Plasmid constructs were sequenced to verify the presence of correct insert. A pGL3 plasmid construct containing the -1 to -150 bp proximal region of the CD14 promoter was prepared as described previously [30] . Site-directed-mutagenesis at the proposed sites of MZF-1 binding was done according to the manufacturer's protocol (Stratagene QuickChange sitedirected mutagenesis kit) with the following primers (changes are highlighted in bold): CD11b forward primers with 3 nucleotides changed in the MZF-1 binding sequence 5Ј-GTTTGGGTCAGGAGCTTTTGAGGAAGGGTGGG-CAGGCTGTG-3Ј and reverse primer 5Ј-CACAGCCTGCCCACCCTTCCT-CAAAAGCTCCTGACCCAAAC-3Ј CD14, forward primer 5Ј-CGGAGGAA-GAGAGGTATAGAGGTGATCAGGGTT-3Ј and reverse primer 5Ј-AACCCT-GATCACCTCTATACCTCTCTTCCTCCG-3Ј.
Transient transfections and luciferase reporter assay
HeLa cells were grown to 70% confluence, then subcultured without antibiotics in 12-well plates (0.2 million cells/well) overnight. Lipofectamine 2000 (Invitrogen) was used according to the protocol provided for the transient cotransfection of 0.5 g of the pGL3 reporter construct of interest with 0.25 g (both per well) of pRL-TK (Promega) (to control for transfection efficiency). Approximately 6 h after transfection, cells were treated or not with a PI3K inhibitor, either LY294002 (10 M) or wortmannin (50 nM), for 45 min before the addition (or not) of calcitriol (100 nM ϫ 30 min). PI3K inhibitors were added in again after 24 h of culture. After a total of 72 h, cells were washed with HBSS, and cell lysates were prepared using passive lysis buffer according to the instructions provided (Promega, dual luciferase assay kit). Protein concentrations were measured using Bio-Rad protein assay kit. Prior to measurement of luciferase activity, cell lysates were adjusted with lysis buffer, resulting in samples with identical protein concentrations. Dual luciferase activity was examined using an EG&G Berthold microplate luminometer (LB96V; Berthold Technologies, Dresden, Germany) and reported as ratios of Photinus pyralis luciferase (Pp-luc)/Rr-luc.
Western blot analysis
After agonist and inhibitor treatments, cells were pelleted and washed with HBSS once, then lysed with modified radioimmunoprecipitation assay buffer (50 mM Tris pH 7.4, 1% IPEGAL, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na 3 VO 4 , 1 mM NaF, and protease inhibitor cocktail), and incubated on ice for 10 min. Samples were boiled for 7 min and then centrifuged at 11,000 rpm for 1 min at room temperature. Samples were separated in a 10% SDS-polyacrylamide gel, then transferred to nitrocellulose membrane, and probed with anti-MZF-1 (mouse IgG) or actin (goat IgG) antibodies, followed by washing and incubation with HRP-conjugated secondary antibodies. Blots were developed using enhanced chemiluminescence solution (Amersham).
Cell surface expression of CD11b and CD14
After agonist and inhibitor treatments, THP-1 cells were washed with binding buffer (HBSS, 10% FBS, 0.1% NaN 3 ) and then incubated for CD14 detection with mAb 3C10 antibody in binding buffer (containing 1% normal mouse serum to reduce nonspecific binding) or for CD11b with 10% FITC-conjugated CD11b antibody (Invitrogen, Caltag Laboratories) in binding buffer (containing 1% mouse IgG to reduce nonspecific binding). After 30 min at room temperature, cells were washed and anti-CD14-treated cells were incubated with FITC-conjugated mouse IgG antibody for 30 min at room temperature. After antibody treatments, cells were washed with binding buffer and fixed with 5% formaldehyde and analyzed using a BD Biosciences FACSCalibur flow cytometer. Data were acquired using BD CellQuest software and analyzed with WinMDI V2.9 software (Joseph Trotter).
Silencing of MZF-1
Small interfering (si)RNA was used to down-regulate MZF-1 expression. THP-1 cells were grown to a concentration of 0.5 ϫ 10 6 cells/ml in RPMI 1640 medium supplemented with 10% FBS without antibiotics. Three different siRNA sequences were used to target human MZF-1 (GenBank accession number NM_003422.2): #1 5Ј-CCAGCGAUCUGAGGAGUGAACAGGA-3Ј, #2 5Ј-GACAAGUCCUUUGGCUGCGUCGAGU-3Ј (Invitrogen), and #3 5Ј-UUUCCGGUGCUUCCACUAUTT-3Ј (Sigma-Proligo, Woodlands, TX, USA). THP-1 cells were transected with siRNAs at a final concentration of 100 nM using DharmaFECT-2 Dharmacon RNA Technology), according to the protocol provided by the manufacturer. Cells were then incubated overnight at 37°C at 5% CO 2 , after which they were washed with warmed HBSS, then resuspended in complete RPMI and incubated for 72 h. Equal amounts of cells were removed as analyzed for MZF-1 content by Western blot analysis. In parallel experiments, MZF-1-silenced cells were incubated with calcitriol and CD11b and CD14 mRNA levels (after 24 h of calcitriol), and surface expression (after 48-72 h of calcitriol) were measured using qPCR and flow cytometry, respectively.
RT-qPCR analysis of mRNA levels of CD14 and CD11b
After silencing of MZF-1 and 24 h postaddition of calcitriol, 5 ϫ 10 6 cells for every condition were washed with HBSS then collected by centrifugation. Total RNA was isolated using an RNeasy Kit (Qiagen). cDNA was synthesized using SuperScript first-strand synthesis system for RT-PCR (Invitrogen). Briefly, 5 g of total RNA was reverse transcribed in a 20-l reaction volume for 50 min at 42°C with SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen Life Technologies) and oligo dT15 primer, according to the manufacturer's protocol. Real-time PCR with LightCycler System, OPTICON MJ Research, Inc. (South San Francisco, CA, USA) was performed in a reaction mixture of 25 l using the DYNAMO SYBR Green PCR kit (FINNZYMES MJ Research), according to the manufacturer's instruction. Primers designed for analysis were CD11b Forward 5Ј-GCCGGTGAAATATGCTGTCT-3Ј and CD11b reverse 5Ј-GCGGTCCCATATGACAGTCT-3Ј and CD14 forward 5Ј-GCCCTTAC-CAGCCTAGACCT-3Ј and CD14 reverse 5Ј-CCCGTCCAGTGTCAGGTTAT-3Ј. mRNA levels were analyzed relative of those for ␤-actin. Actin primer sequences were, forward 5Ј-TGACGGGGTCACCCACACTGTGCCCATCTA-3Ј and reverse 5Ј-CTAGAAGCATTGCGGTGGACGATGGAGGG-3Ј. The PCR mixtures were incubated for 3 min at 95°C, and amplification was performed for 40 cycles, consisting of denaturation at 94°C for 15 s, annealing at 60°C for 15 s, and extension at 72°C for 20 s. Melting curve analysis was performed from 65°C to 95°C. Real-time PCR was performed in duplicate with a 25-l reaction mixture containing 1 l of cDNA, 400 nm each of the primers and 23 l of 1ϫ master mix.
RESULTS
1␣,25-dihydroxyvitamin D3 induces binding of MZF-1 to an MZF-1 binding element dependent upon PI3K
Incubation of immature myeloid cells with calcitriol induces their differentiation into mature monocytes and macrophages. This is reflected by increased surface expression of both CD11b and CD14, and this response is regulated by PI3K [22] . To identify potential transcription factors responsible for these effects of calcitriol, we analyzed the 450 bp proximal promoters of CD14 and CD11b, which have been shown to be important for regulating gene expression [23, 27] using TFSEARCH (http:www.cbrc.jp/research/db/TFSEARCH.html). In the regions encompassing -150 bp upstream from the transcription start sites of both CD11b and CD14, several candidate MZF-1 binding sites were found (Fig. 1, A and B) . These were of potential interest since MZF-1 has previously been shown to regulate hematopoiesis and to be preferentially expressed in myeloid cells [32] . In the -150 proximal region of the CD11b promoter, three candidate MZF-1 binding sites were identified (Fig. 1A) , with 70 -80% homology to the consensus MZF-1 binding sequence AGTGGGGA [33] . In the CD14 promoter, one candidate site was identified at -89 to -79 (Fig. 1B) with 98% homology to the MZF-1 consensus binding sequence. Oligonucleotides corresponding to these potential binding sites were designed for use in electrophoretic mobility shift assay. We found that treatment of THP-1 cells with calcitriol for 30 min increased DNA binding activity to one of the three candidate sequences in the CD11b promoter ( Fig. 2A) . This sequence was located at position -132 to -123 in CD11b, and of the three candidate sequences, it had the highest degree of homology to the MZF-1 consensus sequence (80%). In addition, calcitriol treatment induced increased protein binding to the single candidate MZF-1 sequence identified in the promoter of CD14 (Fig. 2B) . Of interest, this site and the active sequence in the promoter of CD11b were identical except for a single nucleotide difference. In addition, preincubation of cells with PI3K inhibitors, either wortmannin or LY294002, abrogated hormone-induced activation of MZF-1 for binding to the active sites in both promoters (Fig. 2, A and B) . Competition assays carried out using unlabeled wild-type oligonucleotides (Fig. 2, B and C) , as well as a mutated oligonucleotide (Fig. 2C) carrying a single base pair mutation, revealed that transcription factor binding to the putative MZF-1 binding sites was sequence specific. Thus, in the presence of excess unlabeled wild-type CD14 oligonucleotide (Fig. 2B) or CD11b oligonucleotide (Fig. 2C) , no binding of MZF-1 to labeled oligo was seen. In contrast, the addition of excess mutated CD11b oligonucleotide failed to displace MZF-1 binding (Fig. 2C) .
To confirm the identity of the transcription factor that was binding to the candidate MZF-1 site in CD14, an antibody specific for MZF-1 was used to conduct supershift assays. The addition of MZF-1 antibody resulted in either a supershift of the protein-DNA complex or blocked its formation entirely (Fig. 2D) , depending upon whether the antibody was added to the incubation prior to the addition of oligo and nuclear extract, or simultaneously. This result confirmed that the DNA binding protein in question was indeed MZF-1. Taken together, the results shown in Fig. 2 are consistent with a model in which calcitriol activates binding of MZF-1 to specific sequences in the proximal promoters of both CD14 and CD11b.
The -20 to -150 regions of the proximal CD11b and CD14 promoters are transcriptionally activated by calcitriol dependent upon both PI3K and MZF-1
The -150 bp of the proximal region of CD11b promoter, which was cloned into the pGL3-basic vector, was analyzed for transcriptional activity using a luciferase reporter assay. The results from three independent experiments showed that treatment with calcitriol activated the 150-bp proximal promoter regions in a consistent manner (Fig. 3A) . Notably, pretreatment of cells with PI3K inhibitors, either LY294002 or wortmannin abrogated hormone-induced increases in promoter activity. In fact, promoter activity was reduced significantly below that of untreated control cells, suggesting that basal MZF-1 promoter activity was also regulated by PI3K. We also examined the -1 bp to -150 bp region of the CD14 promoter and found this again to be transcriptionally activated by calcitriol in a PI3K dependent manner (Fig. 3B) as we had reported previously [30] .
Next, we used site-directed-mutagenesis to determine whether these responses were dependent upon the putative sites in these promoters. We changed three nucleotides in the active MZF-1 binding sites in the promoters, changing AGCT-GGGGAG to AGCTTTTGAG in CD11b and GAGGTGGG-GAGG to GAGGTTATGAGG in CD14. Whereas the wild-type reported plasmids showed clear activation in response to cal- citriol, cells transfected with the mutated constructs were essentially unresponsive to hormone treatment. These results provide direct evidence that MZF-1 is involved in bringing about transcriptional activation of both CD11b and CD14 in response to calcitriol.
Treatment of immature myeloid cells with calcitriol induces MZF-1 expression
Two isoforms of MZF-1 have been identified with approximate subunit sizes of 54 and 82 kDa [34] . To examine which isoform may be involved in monocyte/macrophage differentiation, we incubated THP-1 cells with either calcitriol or PMA for 48 h and examined MZF-1 levels by Western blot analysis. Calcitriol brought about a clear increase in expression of the 82-kDa MZF-1 isoform only (Fig. 4) , and the magnitude of this response was comparable to that seen in response to PMA (Fig.  4) . In contrast, expression of the 54-kDa isoform of MZF-1 was not affected by treatment with either hormone or PMA (Fig. 4) .
MZF-1 is required for up-regulation of transcript abundance of both CD11b and CD14 in response to calcitriol
We used siRNA combined with qPCR [35] to examine whether the expression of either CD11b or CD14 or both was dependent upon MZF-1. THP-1 cells were transfected separately with three different siRNA constructs in attempts to silence MZF-1. As shown in Fig. 5 , a 50% to 70% decrease in MZF-1 was observed by day 3 after the addition of siRNA, and this was the maximum silencing that we were able of achieving. We also used an irrelevant siRNA as a control transfection and ethanol as a vehicle control.
To investigate the requirement for MZF-1 in regulating transcript levels of CD11b and CD14, after silencing of MZF-1, cells were incubated with or without calcitriol and after 3 days, total RNA was extracted and converted to cDNA for quantitative real-time PCR. As expected, in control cells, induction of both CD11b and CD14 expression was observed at 48-72 h after incubation with hormone (Fig. 6, A and B) . Similar kinetics were also observed in MZF-1 silenced cells. In the latter, however, transcript abundance for both CD11b (Fig. 6A) and CD14 (Fig. 6B ) was significantly reduced (maximum inhibition, Ͼ90% for CD11b and ϳ70% for CD14). These findings indicate that MZF-1 is required for activation of transcription of both CD11b and CD14 in response to calcitriol.
MZF-1 is required for maximal cell surface expression of CD11b and CD14
We also used siRNA to examine whether cell surface expression of either CD11b or CD14 was dependent upon MZF-1. THP-1 cells were transfected with either of three different siRNA constructs and after MZF-1 silencing, samples were incubated or not with calcitriol for an additional 72 h. Analysis by flow cytometry showed that in cells with reduced levels of MZF-1, there was significant inhibition of surface expression of both CD11b and CD14 (Fig. 7) . Notably, however, MZF-1 silencing had a greater impact on mRNA levels for CD14 and CD11b when compared with its impact on cell surface expression of these differentiation markers. Fig. 3 . Reporter assays show that the proximal promoters of CD11b and CD14 have promoter activity dependent upon MZF-1 sites. Plasmid constructs containing 150 bp of the proximal promoters of CD11b (A) and CD14 (B) were made using pGL3-basic. Wild-type and mutated plasmid constructs were cotransfected into HeLa cells with pRL. Transfected cells were treated or not with PI3K inhibitors for 45 min, then treated or not with calcitriol for 72 h. Cells were then lysed and analyzed for luciferase and renilla expression. Results are reported as relative luciferase activity (sample/control) and are the means Ϯ SE from three independent experiments. Site-directed mutagenesis (from AGCTGGGGAG to AGCTTTTGAG) of the MZF-1 site in CD11b (A) and (from GAGGTGGGGAGG to GAGGTTATGAGG) of the MZF-1 site in CD14 abolished calcitriol-induced promoter activity. 
DISCUSSION
Calcitriol is known to modulate multiple aspects of host immunity including the differentiation and activation of cells of the myeloid lineage [36 -41] . CD11b and CD14 are important differentiation markers known to be induced by calcitriol [22] , but the absence of a VDRE in the proximal promoters of the corresponding genes ( Fig. 1) indicates that this likely does not involve classical genomic signaling. On the other hand, when we analyzed the proximal promoters of CD11b and CD14 we detected several sites that appeared to be good candidate binding sequences for MZF-1 (Fig. 1) . Based upon the detection of these putative MZF-1 binding sites, combined with preferential expression of MZF-1 in myeloid cells [42] and its role in regulating differentiation, we inferred that MZF-1 may be involved in the response to calcitriol. This prediction turned out to be correct as the results presented above show that treatment of immature mononuclear cells with calcitriol brought about activation of MZF-1 in a PI3K dependent manner (Fig. 2, A and B ). This in turn led to induction of the proximal promoters of CD11b and CD14 through what we have now shown to be functional, calcitriol responsive MZF-1 binding sites (Fig. 3, A and B) . These results establish that MZF-1 is positioned downstream of PI3K in a calcitriol induced signaling pathway leading to myeloid cell differentiation.
MZF-1 belongs to the Kruppel family of zinc finger proteins and contains 13 C 2 H 2 zinc fingers, with fingers 1-4 being found in one domain and the remainder located in a second domain. The MZF-1 gene is located on chromosome 19 and encodes multiple transcripts that are translated into three isoforms: MZF-1, MZF-1B and MZF-1C, with MZF-1 and MZF-1B being the major isoforms. MZF-1 is a 438 aa, 54 kDa protein containing all 13 zinc fingers, while MZF-1B is a 734 aa 82 kDa protein containing all 13 zinc fingers plus a SCAN binding domain [34] . SCAN [SRE-ZBP, CTfin51, AW-1 (ZNF174), and Number 18 cDNA] is a conserved motif of 84 residues found predominantly in zinc finger DNA binding proteins in vertebrates. The SCAN domain has oligomerization function and allows self-association or association with other SCAN-domainbearing proteins [43] .
MZF-1 has been shown to be preferentially expressed in myeloid progenitor cells [33] and transcript levels were observed to increase during retinoic acid-induced granulocytic differentiation in HL60 cells [44] . MZF-1 also has been shown to play a key role in regulating gene transcription, such as c-myb and CD34 in embryonic stem cells [45, 46] and PADI1 during keratinocyte differentiation [47] . In addition, when antisense oligonucleotides directed against MZF-1 were used, this was found to block granulocyte colony formation induced by granulocyte colony stimulating factor [32] . Taken together, these findings provide support for a model in which MZF-1 regulates myeloid cell differentiation and hematopoiesis.
Differentiation of myeloid cells involves broad based and tightly regulated changes in gene expression induced in response to diverse cytokines, growth factors and other agonists [36, 43, 48, 49] . Expression of CD11b and CD14 is upregulated during myeloid cell differentiation and their promoters have binding sites for a number of different transcription factors such as Sp-1 [27] , CREB [30] , PU-1 [23] and GATA-2 [43, 50] . Although the detailed hierarchy of the actions of each of these transcription factors and their cognate binding sites is not completely understood, the results of the present study show clearly that calcitriol induced MZF-1 binding activity under the control of PI3K within 30 min of cell treatment (Fig.  2, A and B) . This was associated with a marked increased in transcript expression for both CD11b and CD14 (Fig. 6, A and  B) . Functional evidence that MZF-1 was required for this response was obtained through gene silencing. Here we found that even a 50 to 70% decrease in MZF-1 expression was sufficient to inhibit CD11b and CD14 transcript levels by respectively 90% and 70% (Fig. 6, A and B) . Notably, the impact of silencing MZF-1 on expression of CD11b and CD14 was much greater at the level of transcript accumulation than it was at the level of cell surface expression (Fig. 7, A and B) . Although the reasons for this dichotomy are not clear, one potential explanation is the influence of either translational or post-translational mechanisms which may compensate for reduced transcript levels by increasing the expression of membrane CD11b and CD14. The potential for such compensatory mechanisms is consistent with a recent report showing that lovastatin treatment increased the expression of membrane CD14 in RAW264.7 macrophages without any significant change in mRNA levels [51] . Of additional interest, in this same study increased expression of membrane-bound-CD14 was accompanied by reduced secretion of soluble CD14, suggesting dynamic post-transcriptional and post-translational regulatory mechanisms.
On the basis of our findings and those reported previously, we believe that the expression of CD11b and CD14 is highly regulated, with the involvement of multiple different transcrip- Fig. 6 . Induction of CD11b and CD14 mRNA accumulation in response to calcitriol is dependent upon MZF-1. After silencing of MZF-1, as described in the legend to tion factors. Moreover, just as it has become clear that multiple transcription factors may interact with each other to modulate the expression of a wide variety of genes [52, 53] , this is also likely to be the case for CD11b and CD14 [54, 55] .
A principle finding of this report is that MZF-1 activity appeared to be under the control of a PI3K signaling pathway. As far as we are aware, this is the first report documenting that PI3K can regulate MZF-1. It is also worth noting that the proximal promoters of both CD11b and CD14 contain Sp-1-like sequences located in close proximity to or overlapping with the calcitriol-responsive MZF-1 sites that we identified. Specifically, we found two MZF-1 binding sites within the region spanning -132 to -107 (GCTGGGGAGGAAGGGTGGGC-AAGGG) of the CD11b promoter and the Sp-1 binding site is located at the overlapping -116 to -107 position (highlighted in boldface above). In the CD14 promoter, the Sp-1 binding sequence located at position -90 to -82 (GAGGTGGGG) overlaps nearly completely with the active MZF-1 binding site (Fig.   Fig. 7 . Surface expression of CD14 and CD11b after RNAi treatment. After silencing MZF-1 as described in the legend to 1B). These observations are of particular interest for two reasons. First, expression of CD11b and CD14 has been shown to be influenced by Sp-1 [28, 55, 56] and second, the activity of Sp-1 itself is regulated by PI3K downstream of PKC [56] . Sp-1 is a ubiquitous transcription factor in mammalian cells, and its activity appears to be influenced by both phosphorylation and glycosylation, as well as by the specific sequences of its binding sites [57] . Sp-1 and MZF-1 both belong to the Kruppel family of transcription factors and both bind to GC-rich DNA sequences [33, 57] . Furthermore, it has been reported that Sp-1 interacts with other transcription factors, such as the receptor for calcitriol (VDR) and MEF2D [55, 58] . It has also been found that MZF-1 and Sp-1 can bind to highly similar sequences, as well as to each other and attach to target DNA [59] . Taken together, these several lines of evidence suggest the possibility that calcitriol may modulate the activities of both MZF-1 and Sp-1 in a PI3K-dependent manner, leading to changes in the expression of both CD11b and CD14.
One additional point to consider is the potential contribution of extracellular signal-regulated kinases (ERK) to the calcitriol responses that we describe in this report. Using ERK inhibitor PD098059, we observed blunted responses to calcitriol (data not shown), and this was in agreement with published evidence that induction of CD14 and CD11b in response to hormone is ERK dependent [60] . Whereas this observation may be explained on the basis of proposed cooperation between PI3K and ERK in regulating Sp-1 [56, 61] , it is also possible that MZF-1 activity is dually regulated by these pathways. Initial results that we have obtained showing that inhibition of ERK eliminated MZF-1 DNA binding activity (data not shown) are consistent with such a model and is currently the focus of ongoing studies.
In summary, we show for the first time that calcitriol treatment of immature human mononuclear phagocytes brings about PI3K-dependent activation of MZF-1 DNA binding activity. This is associated with increased binding of MZF-1 to specific sites in the proximal promoters of both CD11b and CD14 and MZF-1-dependent increases in promoter activity. Taken together with other observations reviewed above, these findings show that VDRE-independent responses to calcitriol leading to myeloid cell differentiation likely involve the activity of multiple transcription factors, at least some of which are regulated by PI3K.
